Compare BRAI & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BRAI | RAPP |
|---|---|---|
| Founded | N/A | 2022 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2024 |
| Metric | BRAI | RAPP |
|---|---|---|
| Price | $7.21 | $37.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $48.50 |
| AVG Volume (30 Days) | 14.9K | ★ 329.7K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.62 | $7.73 |
| 52 Week High | $32.32 | $42.27 |
| Indicator | BRAI | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 29.18 | 58.39 |
| Support Level | $6.62 | $25.48 |
| Resistance Level | $8.27 | $41.59 |
| Average True Range (ATR) | 1.28 | 2.18 |
| MACD | -1.10 | 0.06 |
| Stochastic Oscillator | 3.65 | 59.30 |
Braiin Ltd is an Australian technology company leveraging proprietary intellectual property and patented artificial intelligence/machine learning (AI/ML) technologies to deliver actionable insights across the verticals: Agriculture, Property Technology, and Customer Experience as a Service (CXaaS). The company's platforms are designed to address inefficiencies and drive data-backed decision-making across traditionally analog sectors. It prominently focuses on the agriculture technology sector, where it has successfully deployed its AI-powered solutions across multiple implementations. It provides end-to-end solutions to improve farming productivity using IoTs, Wireless Connectivity, Robotics, Software and AI/ML.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.